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Conclusions: 3D image-guided BT allows accurate 
identification of uterine perforations, preventing potential 
acute and long term complications, while ensuring that the 
appropriated dose is delivered to the target volume. 
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Purpose/Objective: Compare the dosimetry for plans 
generated by using the GEC –ESTRO guidelines with a 
traditional point A prescription in terms of tumourcoverage 
and dose to the OARs. 
Materials and Methods: The plans of 30 patients with 
cervical cancerwere reviewed, they all received EBRT to 
45Gy in 25 fractions with concurrentcisplatin chemotherapy. 
They had 3 CT guided individualised fractions of HDR 
brachytherapyaiming for a d90 >80Gy whilst respecting the 
published OARs dose constraints.These were compared with 
plans generated using the 3 CT plans for each patientto 
deliver a prescription of 7Gy to point A. The plans were 
compared in termsof the d90 to the HRCTV, v100 receiving 7 
Gy/ fraction, and the 2cc doses tobladder, rectum, sigmoid, 
small bowel and GI total. We also compared the d90per cm3 
of HRCTV as a surrogate of treatment delivery efficiency. 
Thepaired t-test (T) and pearson correlation coefficient (r) 
were used with2-tailed significance testing level of 0.05. 
Results: A total of 90 individualised plans were compared 
with 90 plans using point A prescription. The median HRCTV 
volume was 30.7cm3(20.1 – 72.4cm3), the total combined 
doses to point A for eachtechnique were comparable with a 
median dose of 75Gy for individualised planning and 73.6Gy 
for plans prescribed to point A. Descriptive data 
comparingthe 2 plans is in table 1: 
 
 
There was a statistically significant difference in the d90 
doses achieved by individualised planning compared to 
prescribing to point A,also only 4 (13%) cases using IGBTfailed 
to achieve a dose of >80Gy compared to 19 cases (63%). 
Although the median doses to the OARs were higher for 
individualised plans, this is contrasted by the number of 
cases who would have received clinically significant doses 
above the accepted dose constraints when prescribing to 
point A, where 2 cases would have received doses of 88.4 Gy 
and 90.9 Gy to the small bowel for a non-individualised plan. 
When looking at the impact of the HRCTV volume on the dose 
delivered to the tumour there was a negative correlation for 
both techniques. There was a stronger association for point A 
prescribing(r=-0.87; p<0.0001) compared to individualised 
planning (r=-0.52;p<0.003). Conforming the dose to the 
tumour volume and shape appears to mitigate for the 
negative effect of large HRCTV volumes. 
Conclusions: Individualised treatment planning for each 
brachytherapyfraction using CT scans allows an increase in 
the number of patients achievinga d90 of >80Gy whilst 
staying within the OARs dose constraints. Prescribingto point 
A without conforming the dose withimage guidance can result 
in a number of patients receiving clinicallysignificant 
overdoses to the OARs with most likely serious long term 
toxicity. 
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Purpose/Objective: To assess the impact of dose constraints 
on the clinical outcome in radio(chemo)therapy and MRI 
based image-guided adaptive brachytherapy (IGABT) for 
cervical cancer. 
Materials and Methods: Our study population consists of 225 
consecutive cervical cancer patients (FIGO stages IB - IVA) 
treated between 1998 – 2008 by external beam radiotherapy 
(EBRT) +/- chemotherapy and IGABT. For this retrospective 
study patients were stratified into two treatment groups: 
Group 1 (optimal treatment): all dose constraints fulfilled. 
Group 2 (suboptimal treatment): one or more dose 
constraints not fulfilled. The following dose constraints (EBRT 
+ brachytherapy dose) were applied: CTVHR D90 ≥85 Gy, D2cc 
rectum < 70 Gy, D2cc bladder <90 Gy. All doses were 
calculated by summation of the dose of all EBRT and 
brachytherapy fractions using the EQD2 model (α/β=10 Gy for 
target volume and α/β =3 Gy for OARs). Differences in event 
free interval [local tumor control and grade 4 toxicity 
(surgery necessary) according to LENT-SOMA score] were 
compared between the two treatment groups. 
Results: Optimal treatment received 77 (34%) and suboptimal 
148 (66%) of the patients. The mean follow-up in group 1 and 
group 2 was 54 and 49 months, respectively. FIGO stage in 
group 1 versus group 2 was: stage I 14 (18%) vs. 11 (7%), p= 
0.015, stage II 49 (64%) vs. 88 (60%), p= 0.545, stage III 14 
(18%) vs. 39 (26%), p= 0.172 and stage IV 0 (0%) vs. 10 (7%), 
p=0.020. There was a significant difference in the volume of 
HRCTV between the two groups (Group 1 vs. group 2: 34.2 
cm³ vs. 47.8 cm³, p=0.001).  
Five-year local recurrence free interval was 92.8% in group 1 
and 80.8% in group 2 (p=0.028). Grade 4 rectal toxicity was 
observed in 2 cases in group 1 and 1 case in group 2. Grade 4 
bladder toxicity was observed in 0 cases in group 1 and 2 
cases in group 2. Five-year event free interval (local 
recurrence or G4 toxicity) in group 1 and 2 was 90 % and 79% 
respectively (p=0.056). 
